Payment overview · 2025
General Payments
$13,461.58
237 reported records · 35 companies
Healthcare provider profile · identity verified
Michele Degregorio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BLOOMFIELD HILLS, MI · NPI 1306808175
Verified facts
What the public records show
CMS Open Payments records show Michele Degregorio, M.D. received $13,461.58 in general payments during 2025 across 237 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis, Entresto, Farxiga, Jardiance, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 893 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 632 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 893 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,086.90 | 30.4% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $1,850.24 | 13.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,718.75 | 12.8% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $1,209.31 | 9.0% | 29 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$881.10 | 6.5% | 33 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $389.00 | 2.9% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $372.05 | 2.8% | 18 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $360.95 | 2.7% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $274.05 | 2.0% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $270.63 | 2.0% | 11 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $249.35 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.19 | 1.4% | 8 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $185.33 | 1.4% | 11 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.69 | 1.2% | 17 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $141.35 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $139.63 | 1.0% | 8 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $128.42 | 0.9% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $127.60 | 0.9% | 3 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $100.31 | 0.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $86.30 | 0.6% | 4 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $59.91 | 0.5% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $56.64 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.11 | 0.4% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $48.27 | 0.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.40 | 0.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $41.12 | 0.3% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $40.71 | 0.3% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $32.20 | 0.2% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $30.57 | 0.2% | 2 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $29.81 | 0.2% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $28.97 | 0.2% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.09 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.52 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $16.18 | 0.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,277.75 | 5 |
| Food and Beverage | $6,183.83 | 232 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $5,805.65 | 19 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $1,850.24 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $372.05 | 18 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $360.95 | 6 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $321.26 | 2 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $296.21 | 10 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $276.93 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $270.63 | 11 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $264.79 | 21 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $235.13 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $191.19 | 8 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $185.33 | 11 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $157.53 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $157.53 | 2 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $156.04 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $146.59 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.32 | 5 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $128.42 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $127.60 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $124.21 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $121.71 | 10 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $100.31 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $99.28 | 4 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $99.28 | 4 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $86.30 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $71.22 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $50.59 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $47.66 | 6 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $46.98 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.40 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $41.12 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $40.71 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $13.03 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 893 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 632 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 263 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 419 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
95 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
263 | 72 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
419 | 144 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
893 | 242 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
419 | 144 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
632 | 192 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
893 | 242 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1383 | 460 |
| Clopidogrel | Clopidogrel Bisulfate | 1255 | 401 |
| Atorvastatin Calcium | Atorvastatin Calcium | 977 | 303 |
| Eliquis | Apixaban | 893 | 242 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 804 | 272 |
| Furosemide | Furosemide | 689 | 270 |
| Carvedilol | Carvedilol | 671 | 201 |
| Losartan Potassium | Losartan Potassium | 661 | 219 |
| Entresto | Sacubitril/Valsartan | 632 | 192 |
| Lisinopril | Lisinopril | 606 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 173 |
| Metoprolol Tartrate | Metoprolol Tartrate | 524 | 173 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 510 | 169 |
| Hydrochlorothiazide | Hydrochlorothiazide | 422 | 140 |
| Jardiance | Empagliflozin | 419 | 144 |
| Xarelto | Rivaroxaban | 351 | 106 |
| Potassium Chloride | Potassium Chloride | 317 | 113 |
| Spironolactone | Spironolactone | 282 | 107 |
| Farxiga | Dapagliflozin Propanediol | 263 | 72 |
| Repatha Sureclick | Evolocumab | 215 | 53 |
| Amiodarone Hcl | Amiodarone Hcl | 208 | 69 |
| Simvastatin | Simvastatin | 207 | 66 |
| Nitroglycerin | Nitroglycerin | 196 | 98 |
| Ranolazine Er | Ranolazine | 195 | 59 |
| Atenolol | Atenolol | 178 | 49 |
| Ezetimibe | Ezetimibe | 168 | 57 |
| Sotalol | Sotalol Hcl | 155 | 42 |
| Flecainide Acetate | Flecainide Acetate | 143 | 46 |
| Bumetanide | Bumetanide | 130 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 119 | 42 |
| Eplerenone | Eplerenone | 113 | 31 |
| Enalapril Maleate | Enalapril Maleate | 102 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 34 |
| Omeprazole | Omeprazole | 97 | 30 |
| Brilinta | Ticagrelor | 95 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 38 |
| Warfarin Sodium | Warfarin Sodium | 89 | 30 |
| Digoxin | Digoxin | 86 | 35 |
| Metolazone | Metolazone | 78 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 24 |
| Clonidine Hcl | Clonidine Hcl | 68 | 25 |
| Labetalol Hcl | Labetalol Hcl | 63 | 22 |
| Valsartan | Valsartan | 63 | 24 |
| Praluent Pen | Alirocumab | 62 | 15 |
| Amoxicillin | Amoxicillin | 60 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | 17 |
| Midodrine Hcl | Midodrine Hcl | 58 | 29 |
| Verapamil Er | Verapamil Hcl | 57 | 14 |
| Cilostazol | Cilostazol | 56 | 26 |
| Prednisone | Prednisone | 52 | 37 |
| Propranolol Hcl | Propranolol Hcl | 51 | 18 |
| Allopurinol | Allopurinol | 48 | 12 |
| Verapamil Hcl | Verapamil Hcl | 43 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Verquvo | Vericiguat | 41 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | 17 |
| Klor-Con M20 | Potassium Chloride | 38 | 15 |
| Colchicine | Colchicine | 36 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 16 |
| Nifedipine Er | Nifedipine | 33 | 16 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 31 | 11 |
| Chlorthalidone | Chlorthalidone | 30 | 13 |
| Multaq | Dronedarone Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Gabapentin | Gabapentin | 27 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Camzyos | Mavacamten | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | 11 |
| Torsemide | Torsemide | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Famotidine | Famotidine | 21 | suppressed |
| Inpefa | Sotagliflozin | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Azithromycin | Azithromycin | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,461.58 · 237 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRE, AFX2 Bifurcated Endograft System, AMPLATZER AMULET, AMVUTTRA, AURYON LASER SYSTEM 100-120 VAC, AZURE XT DR MRI SURESCAN, Alto Abdominal Stent Graft System, Assure WCD, Attruby, Barostim Neo System, CAMZYOS, CAPVAXIVE, CARDIOMEMS, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, COROFLOW, CT THROMBECTOMY SYSTEM KIT, Cleerly Ischemia, Cleerly Labs, ELIQUIS, ENDOCROSS Device, ENTRESTO, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FLOWTRIEVER CATHETER, S, FUROSCIX, Flexitouch Plus, HAWKONE, IN.PACT ADMIRAL, INSPIRE, Indigo System, JARDIANCE, KENGREAL, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, LEQVIO, LifeVest, MICRA, MITRACLIP, Nimbl, ONPATTRO, OPSUMIT, PAXLOVID, REBLOZYL, SYMPHONY CATHETER, SYMPLICITY G3, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, Tyvaso, UPTRAVI, VERQUVO, WAINUA, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error